Irbesartan. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension

Drugs
J C Gillis, A Markham

Abstract

Irbesartan inhibits the activity of angiotensin II (AII) via specific, selective noncompetitive antagonism of the AII receptor subtype 1 (AT1) which mediates most of the known physiological activities of AII. In patients with mild to moderate hypertension, once daily administration of irbesartan 150 or 300 mg, with or without adjunctive antihypertensive agents, provides effective 24-hour BP control. Irbesartan reduced BP to a similar extent to enalapril and atenolol and to a significantly greater extent than losartan. The combination of irbesartan and hydrochlorothiazide resulted in additive antihypertensive effects. The drug is effective in the elderly and dosage adjustment is not required in these patients or in those with renal or hepatic failure. Preliminary studies evaluating the efficacy of irbesartan in patients with heart failure have produced encouraging results. Irbesartan is very well tolerated and neither the frequency nor the pattern of adverse events differed from those seen in placebo recipients, although headache was significantly more frequent with the latter. Similarly, the incidence of adverse events did not differ significantly between irbesartan and enalapril in patients who received either drug as monother...Continue Reading

Citations

Apr 23, 1999·Pharmacotherapy·I Gavras, H Gavras
Dec 16, 2006·The Journal of Clinical Hypertension·William C Cushman, Jan Basile
Jan 10, 2008·Menopause : the Journal of the North American Menopause Society·Faryal S MirzaEllen W Seely
Mar 12, 2009·Biomedical Chromatography : BMC·Soo Kyung BaeJae-Gook Shin
Aug 28, 2012·Journal of Hypertension·Alessandra Cristina KerkhoffSandra Costa Fuchs
Feb 1, 2020·Journal of Hypertension·Dmitry M Davydov
Jul 24, 2001·Blood Pressure. Supplement·G G Belz
Jan 3, 2001·Anesthesia and Analgesia·M BertrandP Coriat
Feb 18, 2003·Pharmacotherapy·J Herbert Patterson
Apr 23, 2002·Journal of the Renin-angiotensin-aldosterone System : JRAAS·G G BelzC Mang
Mar 22, 2013·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Karly P Garnock-Jones
Aug 13, 2011·Acta Crystallographica. Section E, Structure Reports Online·M S SiddegowdaH S Yathirajan
Jun 21, 2001·The American Journal of Geriatric Cardiology·C E Okereke, F H Messerli
May 22, 2001·Journal of Clinical Pharmacology·L R Schwocho, H N Masonson
Mar 28, 2003·Journal of Huazhong University of Science and Technology. Medical Sciences = Hua Zhong Ke Ji Da Xue Xue Bao. Yi Xue Ying De Wen Ban = Huazhong Keji Daxue Xuebao. Yixue Yingdewen Ban·Shifen GuFandian Zeng
Feb 3, 2006·International Journal of Clinical Practice·R Düsing
Aug 16, 2011·European Journal of Clinical Pharmacology·Chang-Ik ChoiSeok-Yong Lee
Jun 14, 2015·Clinical Pharmacokinetics·Julie SteelandtMichel Tod
Aug 10, 2001·Drug Metabolism Reviews·Z H Israili, P G Dayton
Apr 23, 2002·Journal of the Renin-angiotensin-aldosterone System : JRAAS·P M VanderheydenG Vauquelin
Jun 14, 2003·Journal of the Renin-angiotensin-aldosterone System : JRAAS·Michael A Weber
Jan 25, 2013·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Jeong Bae ParkEun Joo Cho
Mar 6, 2021·JHEP Reports : Innovation in Hepatology·Anna SessaJean-François Cadranel
May 3, 2000·Kidney International·M W Taal, B M Brenner
Dec 5, 1998·Kidney International. Supplement·M Burnier, H R Brunner
Feb 12, 2000·Journal of Medicinal Chemistry·D LeungD P Fairlie

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.